A 72-year-old woman was admitted to the ICU 5 days ago for acute exacerbation of COPD and was intubated. She was started on empirical antibiotics (ceftriaxone + vancomycin) for presumed CAP. She has been on mechanical ventilation for 4 days. Today, she develops a new fever (39.2°C), purulent endotracheal secretions, and a new infiltrate on chest X-ray in the right lower lobe. Blood cultures are negative. What is the most likely diagnosis, and what is the recommended next step in antibiotic management?

Explanation

## Diagnosis: Ventilator-Associated Pneumonia (VAP) **Key Point:** VAP is defined as pneumonia occurring >48 hours after endotracheal intubation. This patient meets criteria: intubated for 4 days, new fever, purulent secretions, and new infiltrate. **High-Yield:** VAP is caused by different organisms than CAP, with higher prevalence of gram-negative rods (including *Pseudomonas aeruginosa*) and *Staphylococcus aureus* (including MRSA). Current empirical CAP therapy (ceftriaxone + vancomycin) does NOT adequately cover *Pseudomonas*. ## VAP vs CAP: Pathogen Differences | Pathogen | CAP | VAP | HAP | | --- | --- | --- | --- | | *Streptococcus pneumoniae* | Common | Rare | Rare | | *Haemophilus influenzae* | Common | Uncommon | Uncommon | | *Pseudomonas aeruginosa* | Rare | Common | Common | | *Staphylococcus aureus* (including MRSA) | Uncommon | Common | Common | | *Enterobacteriaceae* | Uncommon | Common | Common | | Anaerobes | Rare | Rare | Possible | ## Empirical Therapy for VAP **Mnemonic: PACED** — *Pseudomonas*, *Acinetobacter*, *Candida*, *Enterobacteriaceae*, *DRGNB* (drug-resistant gram-negative bacilli) VAP empirical regimens (per IDSA 2016 VAP Guidelines): 1. **Piperacillin-tazobactam** (anti-pseudomonal beta-lactam) 2. **Carbapenem** (meropenem or imipenem) 3. **Ceftazidime or cefepime** (3rd/4th generation cephalosporins with anti-pseudomonal activity) All should be combined with: - **Vancomycin** OR **Linezolid** (for MRSA coverage) - Consider **Fluoroquinolone** (ciprofloxacin) if additional gram-negative coverage needed **Clinical Pearl:** Ceftriaxone (used for CAP) does NOT cover *Pseudomonas*. When VAP is suspected, switch to an anti-pseudomonal beta-lactam (piperacillin-tazobactam, carbapenem, or ceftazidime/cefepime) + vancomycin. ## Why Current Therapy Is Inadequate The patient was started on ceftriaxone + vancomycin for presumed CAP. Ceftriaxone is a 3rd-generation cephalosporin without anti-pseudomonal activity. VAP requires anti-pseudomonal coverage; therefore, **piperacillin-tazobactam or a carbapenem must be added or substituted**. ## Diagnostic Approach 1. **Obtain sputum/BAL culture** (quantitative culture preferred; >10⁴ CFU/mL suggests VAP) 2. **Blood cultures** (already negative, reducing likelihood of bacteremia) 3. **Do NOT delay antibiotics** while awaiting culture results — empirical broad-spectrum therapy is standard 4. **De-escalate** once culture/susceptibilities available